MAIA Biotechnology, Inc. (MAIA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Chicago, IL, United States. The current CEO is Vlad Vitoc.
MAIA has IPO date of 2022-07-28, 13 full-time employees, listed on the NYSE, a market capitalization of $54.9M.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
